Hepatic inflammation and insulin resistance in pre-diabetes - Further evidence for the beneficial actions of PPAR-γ agonists and a role for SOCS-3 modulation

British Journal of Pharmacology

Volumn 160, Issue 8, 2010, Pages 1889-1891

  Chatterjee, Prabal K ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

hepatic; interleukin 6; liver; peroxisome proliferator activated receptor ; pioglitazone; pre diabetes; supressor of cytokine signalling 3; thiozolidinediones; tumour necrosis factor

Indexed keywords

CHOLESTEROL; FRUCTOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AUTACOID; INSULIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOCS3 PROTEIN, RAT; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARBOHYDRATE DIET; CHOLESTEROL DIET; CONTROLLED STUDY; HEPATITIS; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; AGONISTS; ANIMAL; BLOOD; DRUG EFFECTS; HUMAN; LIVER; METABOLISM; PATHOPHYSIOLOGY; PREDIABETIC STATE; SIGNAL TRANSDUCTION;

ANIMALS; HEPATITIS; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; PPAR GAMMA; PREDIABETIC STATE; RATS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; THIAZOLIDINEDIONES;

EID: 77954867626     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00739.x     Document Type: Note

References (20)

1. Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S (2009). Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology 49 : 1636 1644.
2. Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J (2008). Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability. Arch Biochem Biophys 477 : 86 91.
3. Collino M, Aragno M, Catiglia S, Miglio G, Tomasinelli C, Boccuzzi G et al 2010). Beneficial effects of PPARγ agonism in overweight rats fed a Western-type diet involve SOCS-3 hepatic modulation. Br J Pharmacol 160 : 1892 1902.
4. Deng JY, Huang JP, Lu LS, Hung LM (2007). Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose- fed rats. Am J Physiol Heart Circ Physiol 293 : H978 H987.
5. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D (2005). Role of PPAR-gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets Cardiovasc Haematol Disord 5 : 377 386.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 : S5 S20.
7. Gardner OS, Dewar BJ, Graves LM (2005). Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol 68 : 933 941.
8. Hong F, Nguyen VA, Gao B (2001). Tumor necrosis factor alpha attenuates interferon alpha signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J 15 : 1595 1597.
9. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI et al 2009). Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 30 : 96 116.
10. Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y et al 2005). Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 102 : 6207 6212.
11. Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M et al 2007). Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56 : 795 803.
12. Lebrun P, Van Obberghen E (2008). SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf) 192 : 29 36.
13. Miller A, Adeli K (2008). Dietary fructose and the metabolic syndrome. Curr Opin Gastroenterol 24 : 204 209.
14. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS (2008). Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 9 : 1087 1108.
15. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A et al 2006). Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26 : 624 630.
16. Schenk S, Saberi M, Olefsky JM (2008). Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118 : 2992 3002.
17. Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002). Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 : 3391 3399.
18. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW et al 2003). Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278 : 13740 13746.
19. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T et al 1997). Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 272 : E989 E996.
20. Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z et al 2009). Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 29 : 6186 6195.